Human immunodeficiency virus-associated progressive multifocal leucoencephalopathy: Epidemiology and predictive factors for prolonged survival

European Journal of Neurology

Volumn 14, Issue 4, 2007, Pages 418-423

  Drake, A K ^a,g   Loy, C T ^b   Brew, B J ^b,c   Chen, T C C ^d   Petoumenos, K ^c   Li, P C K ^e   Wright, E J ^a,c,f  

^a ALFRED HOSPITAL   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^f MONASH UNIVERSITY   (Australia)

^g FIJI SCHOOL OF MEDICINE   (Fiji)

Author keywords

Antiretroviral therapy; Human immunodeficiency virus; Progressive multifocal leucoencephalopathy; Survival

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CIDOFOVIR; CYTARABINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; AGED; AUSTRALIA; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DEMOGRAPHY; DRUG USE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HONG KONG; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOENCEPHALOPATHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; TREATMENT OUTCOME; VIRUS DIAGNOSIS;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CYTOSINE; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 33947605666     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2007.01686.x     Document Type: Review

References (14)

1. Berger JR, Levy RM, Flomenhoft D, Dobbs M. Predictive factors for prolonged survival in acquired immune deficiency syndrome-associated progressive multifocal leukoencephalopathy. Annals of Neurology 1998; 44: 341-349.
2. Antinori A, Ammassari A, Giancola ML, et al. Epidemiology and prognosis of AIDS associated progressive multifocal leukoencephalopathy in the HAART era. Journal of Neurovirology 2001; 7: 323-328.
3. Berger JR, Pall L, Lanksa D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. Journal of Neurovirology 1998; 4: 59-68.
4. Berger JR, Mucke L. Prolonged survival and partial recovery in AIDS-associated progressive multifocal leukoencephalopathy. Neurology 1988; 38: 1060-1065.
5. De Luca A, Giancola ML, Ammassari A, et al. Potent antiretroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: extended follow-up of an observational study. Journal of Neurovirology 2001; 7: 364-368.
6. Gasnault J, Taoufik Y, Goujard C, et al. Prolonged survival without neurological improvement in patients with AIDS-related progressive multifocal leukoencephalopathy on potent antiretroviral therapy. Journal of Neurovirology 1999; 5: 421-429.
7. Geschwind MD, Skolasky RI, Royal WS, McArthur JC. The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. Journal of Neurovirology 2001; 7: 353-357.
8. Miralles P, Berenguer J, de Viedma DG, et al. Treatment of AIDS-associated progressive multifocal leukoencephalopathy with highly active antiretroviral therapy. AIDS 1998; 12: 2467-2472.
9. Hall C, Dafni U, Simpson D, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus associated infection. The New England Journal of Medicine 1998; 338: 1345-1351.
10. Cysique LA, Maruff P, Brew BJ. Antiretroviral therapy in HIV infection: are neurologically active drugs important? Archives of Neurology 2004; 61: 1699-1704.
11. Giancola ML, Lorenzini P, Balestra P, et al. Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 2006; 41: 332-337.
12. Clifford DB, Yiannoutsos C, Glicksman MS, et al. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 1999; 52: 623-625.
13. Antinori A, Giancola ML, Grisetti S, et al. Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients. AIDS 2002; 16: 1867-1876.
14. Taoufik Y, Gasnault J, Karaterki A, et al. Prognostic value of JC virus load in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. The Journal of Infectious Diseases 1998; 178: 1816-1820.